AZN vs NVS
AstraZeneca PLC and Novartis AG, both Healthcare
Novartis AG is the larger company at $281B against $271B. On trailing earnings NVS is the cheaper of the two at a P/E of 23.3 against 27.4, a gap that is only a bargain if the two are growing at similar rates. Over the past year NVS returned +40% against +13% for AZN. Ryufin's sector-relative Smart Score puts AZN ahead, 9/10 against 8/10.
| Figure | AZN | NVS |
|---|---|---|
| Last close | $166 | $158 |
| Market cap | $271B | $281B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 27.4 | 23.3 |
| 1-year return | +13% | +40% |
| 5-year return | +61% | +106% |
| Ryufin Smart Scoresector-relative, 1–10 | 9/10 | 8/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
AstraZeneca PLC
Revenue of $31B in H2 2025, net income $4.9B.
Novartis AG
Revenue of $27B in H2 2025, net income $6.3B.
Open these two in the interactive comparison to add more names, change the period or read the correlation.